STU 042017-024: NRG-LU002 - Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Cancer (NSCLC): A Randomized Phase II/III Trial.
STU 022015-069: JoLT-Ca/STABLEMATES - A Randomized Phase III Study of Sublobar Resection (SR) versus Stereotactic Ablative Radiotherapy (SAbR) in High-Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC), the STABLEMATES Trial. Learn more about the JoLT-CA/STABLEMATES trial.
STU 2018-0261: ADRIATIC - A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Limited Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC).
STU 2019-0858: PACIFIC 4/RTOG-3515 - A Phase III, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Stage I/II Non-Small Cell Lung Cancer (PACIFIC-4/RTOG-3515).
STU 2019-1082 - A Phase II Concurrent Durvalumab (MEDI4736) and Radiotherapy Followed by Consolidative Durvalumab (MEDI4736) for Stage III Non-Small Cell Lung Cancer (NSCLC).
STU 062016-073: Lung SAbR - Investigating Radiation-Induced Injury to Airways and Pulmonary Vasculature in Lung Stereotactic Ablative Body Radiotherapy (SAbR).
STU 022017-075: Vision RT - VisionRT-Based Deep Inspiration Breath-Hold (DIBH) Respiratory Motion Management Strategy, a Pilot Study for Thoracic and Abdominal Tumors Stereotactic Body Radiotherapy.
STU 2019-1390: Tissue Procurement and Outcome Collection for Cancer Patients With and Without Cachexia.